Table 6.
Association of various clinical factors with leukemic transformation.
| Variables | Leukemic Transformation | |
|---|---|---|
| Odds Ratio (95% CI) | p-Value a | |
| TET2 mutation | 0.170 (0.031–0.924) | 0.040 |
| High miR-22 expression | 0.267 (0.067–1.064) | 0.061 |
| IPSS (higher-risk to lower-risk disease) b | 7.367 (1.836–29.554) | 0.005 |
| IPSS-R (higher-risk to lower-risk disease) b | 4.900 (1.282–18.725) | 0.020 |
| Cytogenetic abnormality | 2.400 (0.654–8.811) | 0.187 |
| Cytogenetic risk categories | 5.833 (1.038–32.797) | 0.045 |
| (higher-risk vs. lower-risk karyotype) c | ||
| Poor-risk gene mutation | 17.733 (3.619–86.885) | 0.000 |
| Response to HMT | 0.592 (0.115–3.061) | 0.532 |
| Elderly (≥70) | 1.575 (0.451–5.504) | 0.477 |
Abbreviations: CI, confidence interval; HMT, hypomethylating therapy; IPSS, International Prognostic Scoring System; IPSS-R, Revised International Prognostic Scoring System; TET2, Tet methylcytosine dioxygenase 2. a p-value was calculated via univariate logistic regression analysis. b Based on the IPSS and IPSS-R, patients are divided into lower-risk disease (IPSS low, intermediate-1; IPSS-R very low, low, intermediate) and higher-risk disease (IPSS Intermediate-2, high; IPSS-R high, very high) groups. c Based on the IPSS-R, cytogenetic risk categories are divided into lower-risk karyotype (IPSS-R very good, good) and higher-risk karyotype (IPSS-R intermediate, poor, very poor).